These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 26260387)

  • 1. The novel function of CD82 and its impact on BCL2L12 via AKT/STAT5 signal pathway in acute myelogenous leukemia cells.
    Nishioka C; Ikezoe T; Takeuchi A; Nobumoto A; Tsuda M; Yokoyama A
    Leukemia; 2015 Dec; 29(12):2296-306. PubMed ID: 26260387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD82 regulates STAT5/IL-10 and supports survival of acute myelogenous leukemia cells.
    Nishioka C; Ikezoe T; Yang J; Nobumoto A; Kataoka S; Tsuda M; Udaka K; Yokoyama A
    Int J Cancer; 2014 Jan; 134(1):55-64. PubMed ID: 23797738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetraspanin Family Member, CD82, Regulates Expression of EZH2 via Inactivation of p38 MAPK Signaling in Leukemia Cells.
    Nishioka C; Ikezoe T; Yang J; Yokoyama A
    PLoS One; 2015; 10(5):e0125017. PubMed ID: 25955299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells.
    Nishioka C; Ikezoe T; Furihata M; Yang J; Serada S; Naka T; Nobumoto A; Kataoka S; Tsuda M; Udaka K; Yokoyama A
    Int J Cancer; 2013 May; 132(9):2006-19. PubMed ID: 23055153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STAT5A regulates DNMT3A in CD34(+)/CD38(-) AML cells.
    Takeuchi A; Nishioka C; Ikezoe T; Yang J; Yokoyama A
    Leuk Res; 2015 Aug; 39(8):897-905. PubMed ID: 26059451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-1β inhibits self-renewal capacity of dormant CD34⁺/CD38⁻ acute myelogenous leukemia cells in vitro and in vivo.
    Yang J; Ikezoe T; Nishioka C; Nobumoto A; Yokoyama A
    Int J Cancer; 2013 Oct; 133(8):1967-81. PubMed ID: 23564444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coexpression of hyperactivated AKT1 with additional genes activated in leukemia drives hematopoietic progenitor cells to cell cycle block and apoptosis.
    Tang Y; Halvarsson C; Nordigården A; Kumar K; Åhsberg J; Rörby E; Wong WM; Jönsson JI
    Exp Hematol; 2015 Jul; 43(7):554-64. PubMed ID: 25931014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-182-5p regulates BCL2L12 and BCL2 expression in acute myeloid leukemia as a potential therapeutic target.
    Zhang S; Zhang Q; Shi G; Yin J
    Biomed Pharmacother; 2018 Jan; 97():1189-1194. PubMed ID: 29136958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express Aurora kinase A.
    Yang J; Ikezoe T; Nishioka C; Nobumoto A; Udaka K; Yokoyama A
    Int J Cancer; 2013 Dec; 133(11):2706-19. PubMed ID: 23686525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia.
    Zeng Z; Samudio IJ; Zhang W; Estrov Z; Pelicano H; Harris D; Frolova O; Hail N; Chen W; Kornblau SM; Huang P; Lu Y; Mills GB; Andreeff M; Konopleva M
    Cancer Res; 2006 Apr; 66(7):3737-46. PubMed ID: 16585200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of BCL2L12 gene in de novo acute myeloid leukemia and its clinical implications].
    Yu MX; Lu Y; Mu QT; Wang Q; Chen ZM; Lou JY; Jin J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Oct; 30(5):544-8. PubMed ID: 24078567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic inhibition of cell migration by tetraspanin CD82 and gangliosides occurs via the EGFR or cMet-activated Pl3K/Akt signalling pathway.
    Li Y; Huang X; Zhang J; Li Y; Ma K
    Int J Biochem Cell Biol; 2013 Nov; 45(11):2349-58. PubMed ID: 23968914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
    Nogami A; Oshikawa G; Okada K; Fukutake S; Umezawa Y; Nagao T; Kurosu T; Miura O
    Oncotarget; 2015 Apr; 6(11):9189-205. PubMed ID: 25826077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of CD82 by a monoclonal antibody potentiates anti-leukemia effects of AraC in vivo.
    Nishioka C; Ikezoe T; Yokoyama A
    Cancer Med; 2015 Sep; 4(9):1426-31. PubMed ID: 26139471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of the novel member of the BCL2 gene family, BCL2L12, is associated with the disease outcome in patients with acute myeloid leukemia.
    Thomadaki H; Floros KV; Pavlovic S; Tosic N; Gourgiotis D; Colovic M; Scorilas A
    Clin Biochem; 2012 Nov; 45(16-17):1362-7. PubMed ID: 22728012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential antigen expression and aberrant signaling via PI3/AKT, MAP/ERK, JAK/STAT, and Wnt/β catenin pathways in Lin-/CD38-/CD34+ cells in acute myeloid leukemia.
    Garg S; Shanmukhaiah C; Marathe S; Mishra P; Babu Rao V; Ghosh K; Madkaikar M
    Eur J Haematol; 2016 Mar; 96(3):309-17. PubMed ID: 26010294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD82 supports survival of childhood acute myeloid leukemia cells via activation of Wnt/β-catenin signaling pathway.
    Ji H; Chen L; Xing Y; Li S; Dai J; Zhao P; Wang Y
    Pediatr Res; 2019 Jun; 85(7):1024-1031. PubMed ID: 30862962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
    Tong H; Ren Y; Zhang F; Jin J
    Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcl2L12 with a BH3-like domain in regulating apoptosis and TMZ-induced autophagy: a prospective combination of ABT-737 and TMZ for treating glioma.
    Yang MC; Loh JK; Li YY; Huang WS; Chou CH; Cheng JT; Wang YT; Lieu AS; Howng SL; Hong YR; Chou AK
    Int J Oncol; 2015 Mar; 46(3):1304-16. PubMed ID: 25586056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of signal transducer and activator of transcription 5 by the inhibitor of janus kinases stimulates dormant human leukemia CD34+ /CD38- cells and sensitizes them to antileukemia agents.
    Ikezoe T; Yang J; Nishioka C; Kojima S; Takeuchi A; Phillip Koeffler H; Yokoyama A
    Int J Cancer; 2011 May; 128(10):2317-25. PubMed ID: 21128225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.